Forskolin

製品コードS2449 別名:Coleonol

Forskolin化学構造

分子量(MW):410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

サイズ 価格(税別)  
In DMSO JPY 25200
JPY 20200
JPY 46800
JPY 63400
JPY 96600
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 MoLvSpVv[3Srb36gRZN{[Xl? M1i3WlExKM7:TR?= MoH3OkBp MoT4bY5kemWjc3XzJJBpd3OyaH;yfYxifGmxbjDv[kBwfmW{ZYjwdoV{e2WmIFvMTGw{KGG2IGO0N|M> MlG4NlY1OzV2OUi=
Mo-DCs M2jqdGZ2dmO2aX;uJGF{e2G7 Mk\rOVAh|ryP NWD1U2lwOjUkgJno MoH2dJJwdW:2ZYOgTWwuOjNicILv[JVkfGmxbjDpckB1cGVic4Xw[ZJv[XSjboSgc4Yhgnmvb4PhckB{fGmvdXzheIVlKE2xLVTDd:Kh NI\tSWwzPjRzMkm0PC=>
RBMECs  MXnGeY5kfGmxbjDBd5NigQ>? NV3Z[lRoPcLizszN M3i1bFHDqGh? M2TjPYJtd2OtczD0bIUhWmGlMTDpcoFkfGm4YYTpc44hcW6mdXPl[EBjgSCHTVHQMWlK MlfKNlY{PThyM{m=
INA-6 MnzpR4VtdCCYaXHibYxqfHliQYPzZZk> MXuwMVExOCEQvF2= NIjyTZg4OuLCiXi= MUfpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MWmyOlMxPjZ{NB?=
OPM-2 MmTtR4VtdCCYaXHibYxqfHliQYPzZZk> MV[wMVExOCEQvF2= NEnoOVE4OuLCiXi= MVnpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= Ml7yNlY{ODZ4MkS=
U266 MnjBR4VtdCCYaXHibYxqfHliQYPzZZk> M{TaTlAuOTByIN88US=> MUC3NwKBkWh? M4fMN4lv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 M4XEdlI3OzB4NkK0
H929 MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUPRXG9iOC1zMECg{txO MYe3NwKBkWh? NVzmVod5cW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> MoHENlY{ODZ4MkS=
RPMI 8226 MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2LGe|AuOTByIN88US=> NELVXXE4OuLCiXi= NXr4clA5cW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> MoPFNlY{ODZ4MkS=
MDCK  MnjjSpVv[3Srb36gRZN{[Xl? Ml7FNVAhyrWP NUfpOmRWOjRiaB?= MnHmSG1UVw>? MXH1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBVT0ZvzsKxJIFv\CCFVFfGxsA> NFjHR2gzPjJyMkO1Ni=>
MDCK  MkP6SpVv[3Srb36gRZN{[Xl? NV3Q[JdrOTBiwsXN MUOyOEBp M3LxXmROW09? NUP1[2JFcW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDlfJBz\XO|aX;uJI9nKE[QIHPheZNm\CCkeTDUS2Yu|rJz NF7HRlEzPjJyMkO1Ni=>
Spinal cords  MlzPSpVv[3Srb36gRZN{[Xl? NE[3UWgyyqEQvF2= M3HWN|MxKG2rbh?= MonEd5RqdXWuYYTld{BkSU2SIHzleoVtew>? M33EOVI3OTJ4OUK2
BeWo  NYm0[mhITnWwY4Tpc44hSXO|YYm= MmnLNlXjiIoQvF2= M2i3bVI1NzR6L{eyJIg> M{DvV4xm[WS|IITvJIFvKGmwY4LlZZNmKGmwIITo[UBmgHC{ZYPzbY9vKG:oIH;0bIVzKG[3c3nvckBu[XKtZYLz M1LVSVI3ODV|NUS5
bovine oocytes NILFOmtHfW6ldHnvckBCe3OjeR?= M3T6T|ExOMLizszN MWmxNuKhcA>? MV7pcohq[mm2czD0bIUh\W[oZXP0JI9nKE6SUFGgZY5lN2:{IF7QVGMhfG9ic4TpcZVt[XSnIILld5VueHSrb36gc4YhdWWrb4Ppdy=> NGGyO4czPjB3MU[xNS=>
Caco-2  Mn;xSpVv[3Srb36gRZN{[Xl? NGT4R|IxNjFxMT:xNEDPxE1? NHrRPFkzOMLibXnu NEDVTYpqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hcW62cnHj[YxtfWyjcjDjRW1RKGyndnXsdy=> MUmyOlA1QTFyMh?=
Caco-2  M{HnVGZ2dmO2aX;uJGF{e2G7 NWK0Vo5bOC5zL{GvNVAh|ryP MnvZNlQhcA>? NXTzWVI2cW6lcnXhd4V{KE2UUEKgdJJwfGWrbjDs[ZZmdA>? NFiyelczPjB2OUGwNi=>
AML-12  MXTGeY5kfGmxbjDBd5NigQ>? MonpNlAh|ryP Mn;yN{Bp M{nuW5VxemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ibHX2[Yx{KGG2IGTodk01OTFiYX7kJHNmei12OUO= M2G5VFI3ODR6OUi1
AML-12  MWLGeY5kfGmxbjDBd5NigQ>? NWTwe3VZOjBizszN M1zHWVEuQCCq NX3URWtwcW6lcnXhd4V{KGeudXPvd4UheHKxZIXjeIlwdg>? MYSyOlA1QDl6NR?=
AML-12  NVTvVJlpTnWwY4Tpc44hSXO|YYm= Mnr5NlAh|ryP MlrHN{Bp Mn;aeZAuemWpdXzheIV{yqCSZ3OxZUzDqFCncHPrMEBidmUEoFe2dIPDqG2UTlGgcIV3\Wy| NHXsRZAzPjB2OEm4OS=>
AML-12  MX7GeY5kfGmxbjDBd5NigQ>? MVKyNEDPxE1? NHqwdnc{KGh? MXrpcoR2[2W|IITo[UBl\XCqb4PwbI9zgWyjdHnvckBw\iCFUmTDNuKh NEnGVoIzPjB2OEm4OS=>
RBMECs M13F[mZ2dmO2aX;uJGF{e2G7 MUe1xsDPxE1? M2\leFEhcA>? NH3ldIhqdmirYnn0d{BGVUGSLVnJMYlv\HWlZXSgbY5i[3SrdnH0bY9vKG:oIGLhdFHDqA>? NFG0VlEzPjB2NE[2Ny=>
EndoC-βH1 MlfGSpVv[3Srb36gRZN{[Xl? NYjPXo9FPcLizszN M{OzVFEhcA>? M1j2VZBwfGWwdHnheIV{KGeudXPvd4UucW6mdXPl[EBqdnO3bHnuJJNm[3KndHnvckBqdiC2aHWgdJJme2WwY3Wgc4Yh\2y3Y3;z[S=> MoTpNlYxOjh3NkK=
EndoC-βH1 NXHLbmlOTnWwY4Tpc44hSXO|YYm= MVe1xsDPxE1? NH61bpIyKGh? M2HWfoxm[WS|IITvJIEhe3S{b37nJINCVVBiaX7jdoVie2V? NXTkWFMxOjZyMki1OlI>
SH-SY5Y MVfGeY5kfGmxbjDBd5NigQ>? NYfTTGVLOzBizszN M{nZeVMxKG2rbh?= MnT1SG1UVw>? Mknzd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIFkfGm4YYTpc44hd2ZiUFvB MViyOlAzPTF|Nx?=
PC-3 NHXrcWZHfW6ldHnvckBCe3OjeR?= NH3n[lQ1OCEEtV2= M3u3ZlIhcA>? MnvCSG1UVw>? MmLUcIVi\HNidH:gVHAzSSCjY4TpeoF1cW:w NV[3OHd2OjZyMkO4N|Y>
PC-3 M3ywXWNmdGxiVnnhZoltcXS7IFHzd4F6 NHHNWG81OCEEtV2= MXuyOE81QC95MjDo NV;hfYJITE2VTx?= NUTkfWVr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRqdWViZHXw[Y5l\W62bIm= NF;HcIEzPjB{M{izOi=>
SCG MYrGeY5kfGmxbjDBd5NigQ>? Mm[1NlAh|ryPwrC= M1;XR2ROW09? MmjJdoV3\XK|aXLsfUB{fXCycnXzd4V{KEmNVjD3bZRpKGFiSVO1NEBw\iB{ND60JO69VQ>? NXL4fZVMOjV7NkKxN|I>
HEK-293 MVPGeY5kfGmxbjDBd5NigQ>? NVv2PGFEOzVizszNxsA> NGnROoRFVVOR NYexUo1wcW6mdXPld{BiKGOxboPwbYN2d3W|IPMAoIlv[WO2aY\heIlwduLCnTDv[kB1cGViS4[yMlEh[3W{cnXueC=> M{Tw[VI2QTZ{MUOy
SCG NX;uO4RvTnWwY4Tpc44hSXO|YYm= NFvLcVkyODBizszNxsA> MV\EUXNQ MnfZdoVlfWOnczD0bIUh\XilaYThZoltcXS7IH;mJHNETyCwZYXyc45{ NFfRcZEzPTl4MkGzNi=>
PCCL3 NH:xWnJHfW6ldHnvckBCe3OjeR?= NUPuVHcyOTBiwsXN NIPDWIkzPCCq MU\lcohidmOnczDEeW95OiCycn;tc5RmeiC2cnHud4NzcXC2aX;uJIFkfGm4aYT5xsDjiIt? NH\GenEzPTl4MEm1Oi=>
3T3-L1 preadipocytes MoLiSpVv[3Srb36gRZN{[Xl? NFnwd3AyOCEQvF5CpC=> MlS3NVIhcA>? NIHXVlNqdmS3Y3XzJGNTTUJicHjvd5Bpd3K7bHH0bY9vKGGwZDDDM2VDWM7{IHX4dJJme3Orb36= NIfHTFEzPTl{OEC1PC=>
H295R  NWnRXnV4TnWwY4Tpc44hSXO|YYm= M2K3dVExyqEQvF2= MnmyOFjDqGh? Mlj2bY5kemWjc3XzJJN1\XKxaXSgcYV1[WKxbHn0[ZMhcW5idHjlJIFv\HKxZ3XuMEBucW6ncnHsc{0h[W6mIHfseYNw[2:{dHnjc4llKHCjdHj3ZZl{ NInjd|czPTh4OUW1Oi=>
PBMC NF7Q[|NHfW6ldHnvckBCe3OjeR?= MXS1NOKh|ryP MXGyOOKhcMLi NXi3S3JHcW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDz[YNz\XSrb36gc4YhXE6IIHnu[JVk\WRiYomgeIhmKESSRR?= NW\h[WdlOjV6Nk[wO|k>
GLUTag  MonLSpVv[3Srb36gRZN{[Xl? MkjJNVDjiIoEtV2= M{jiU|AwOi92IHi= NWXOd|JHe3SrbYXsZZRmeyCJTGCtNUB{\WO{ZYTpc44h[2:2cnXheIVlKHerdHigTWJOYA>? NUjUbXJZOjV6M{K2N|E>
GLUTag  M1jKfWZ2dmO2aX;uJGF{e2G7 NVjuRWtkOTEkgJpCuW0> NWTwXXFOPCCq NEfNWnFqdmO{ZXHz[ZMhfGinIIDDVmVDKGyndnXsd{B4cXSqIITo[UBKSk2[ NFPOTHkzPTh|Mk[zNS=>
BAECs NFXBTpJHfW6ldHnvckBCe3OjeR?= NFrBeVAzPSEQvF2= NVu3VVhYOjRiaB?= M3fiS4VvcGGwY3XzJJRp\SCjY4TpeoF1cW:wIH;mJHBRSVMQsTDifUA2KM7:TTDy[ZN3\XKjdILvcEwhXDSKUzygc5IhPC2SQWC= NEnpeIEzPTd7OEiyOi=>
PC12 NHvsSnNHfW6ldHnvckBCe3OjeR?= MVWyOeKh|ryP NYm4TFNRPDhiaB?= NVq0TJJJ[WO2aY\heIV{KGODTWC= NGXTemczPTd4OUOwOS=>
GH3 NWHH[|RyTnWwY4Tpc44hSXO|YYm= MnraNeKh|ryP NEnkOWE3NWh? MlLXZZR1\W63YYTld{B1cGViY3;ydoVt[XSrb36gZoV1f2WnbjDQVmwh[W6mIFLtZYwyKGW6cILld5Nqd25? Mn\5NlU4OjdyMUi=
GH3 M4PiXGZ2dmO2aX;uJGF{e2G7 MWqxxsDPxE1? NYf2Vm5zPi2q MkH0bY5lfWOnczDQVmwh[W6mIFLtZYwyNCCkdYSgco91KEOub3PrMEBuWk6DIHX4dJJme3Orb36= NHfFVIUzPTd{N{CxPC=>
BeWo NFn3XYlHfW6ldHnvckBCe3OjeR?= NH3rTIgyOOLCit88UeKh NH7INmI4OiCq M2X0WGROW09? NVPlWWp5dWWmaXH0[ZMhSmWZbzDj[YxtKGSrZn\ldoVvfGmjdHnvci=> NGHtT4gzPTdzM{SyOS=>
oocytes MVzGeY5kfGmxbjDBd5NigQ>? MXG1JO69VQ>? NUmzcodQOjRiaB?= M1;GN4F1fGWwdXH0[ZMhemhvaX7zeYxqdiCjY4Tpc44hd25ib3;jfZRmKEeYQlSgd4lodmmoaXPhcpRtgcLi MkjmNlU4ODd6NUS=
SC M{i2SWZ2dmO2aX;uJGF{e2G7 MmfqNE42KM7:TR?= NXjTU5E3OjRiaB?= NVTBUI05dWmvaXPrd{B1cGViZX\m[YN1KG:oIHPBUXAh[W6jbH;nd{BwdiCRMTDhcoQhVUKSIHX4dJJme3Orb36= NI\CRnkzPTdyNUi3OC=>
SC MknoSpVv[3Srb36gRZN{[Xl? MYWwMlUh|ryP NFy5Z|I4OiCq MmLUbY5kemWjc3XzJIJwfGhiS4LvfE0zOCCjbnSgU|Eh\XiycnXzd4lwdiCrbjDhfI9vNXKnbHH0[YQhW0O|IHL1eEBwdmy7IFvyc5guOjEEoB?= MkDmNlU4ODV6N{S=
UACC-647  MU\GeY5kfGmxbjDBd5NigQ>? NVL3VJJ2TE2VTx?= MmG5cIVi\HNidH:gZUBzcXOnIHnuJINCVVBibHX2[Yx{KCiHQ{WwxsA:yqB{MD6zPeKh|ryPKR?= MWeyOVcxOzB{NR?=
UACC-647  NVvKRnVDTnWwY4Tpc44hSXO|YYm= MX:xNOKh|ryP MnTkNVUhdWmw MVnEUXNQ NG\KWXBqdmirYnn0d{BGWkticHjvd5Bpd3K7bHH0bY9v Mo\BNlU4ODNyMkW=
UACC-647  MnvHSpVv[3Srb36gRZN{[Xl? MVixNOKh|ryP NWTzSmt4OTVibXnu M{LkS2ROW09? MW\pcoNz\WG|ZYOg[WVHOiCyaH;zdIhwenmuYYTpc44hdGW4ZXzzxsA> NYjoSXR5OjV5MEOwNlU>
SH-SY5Y  NGXPe5RHfW6ldHnvckBCe3OjeR?= M4K5VVExyqEQvF2= MmHINeKhcMLi NYXwRWpwcW6lcnXhd4V{KEyXQzDhZ5Rqfmm2eR?= NWfk[XFxOjV3OUe0N|M>
SH-SY5Y  NX;ySYF5TnWwY4Tpc44hSXO|YYm= M3nqXlExyqEQvF2= MX:xxsBpyqB? MnHIbY5kemWjc3XzJGFISzFibWLORUBt\X[nbB?= M{T2e|I2PTl5NEOz
hADSCs NVLjWnVPTnWwY4Tpc44hSXO|YYm= MVi15qCKyrWP MXKzNEBucW5? M3rvTIlv[3KnYYPld{BkSU2SIHzleoVtew>? M17YVVI2PTlzOUC4
HEK293  M1e2UmZ2dmO2aX;uJGF{e2G7 NVLPZ5A2PeLCidM1US=> MX[zNEBucW5? NHTtZZJqdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN? MoTjNlU2QTF7MEi=
3T3-L1 MlL5SpVv[3Srb36gRZN{[Xl? NHfJV2MzNjVxNTFOwG0> NWXiNmVUOjRiaNMg MnPjd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQWTHUEBxem:2ZXnuJIV5eHKnc4Ppc44h[XRiYXzsJIRwe2W|IITld5Rm\A>? MkTINlU2QTB3OUe=
OCI-Ly1  NHWwToxHfW6ldHnvckBCe3OjeR?= MWe0NOKh|ryP M4PoXlHDqGkEoB?= Ml;3SG1UVw>? MmH6bY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= NEDac5czPTV5NkKyNC=>
OCI-Ly18  Ml;2SpVv[3Srb36gRZN{[Xl? NGTseVM1OMLizszN MmC3NeKhcMLi NVT5fYFETE2VTx?= NFjZTm5qdmS3Y3XzJJRp\SCrbnPy[Y1mdnRib3[gZ2FOWCClb37j[Y51emG2aX;udy=> M{nEc|I2PTd4MkKw
BeWo NGHicJlHfW6ldHnvckBCe3OjeR?= MmHFNlDDqML3TR?= MYW0POKhcA>? MXrEUXNQ MVjpcoNz\WG|ZYOgeIhmKGSrZn\ldoVvfGmjdHnvckBw\iCEZWfvJINmdGy| NHjzdYkzPTV4Nke0NC=>
BeWo MV7GeY5kfGmxbjDBd5NigQ>? NULhfGc1OjEEoNM1US=> NVnDcGtUPDkEoHi= NFm2TYFFVVOR NYrPRlhJcW6lcnXhd4V{KHSqZTDh[Ihme2mxbjDv[kBVUFBvMTDtc45w[3m2ZYO= NVvUbGFoOjV3Nk[3OFA>
LNCaP  M4fRbGZ2dmO2aX;uJGF{e2G7 NVu1XHVROTEEoN88US=> NITHdZAyOiCqwrC= NILHfIZFVVOR NEm2SWVqdmS3Y3XzJIEh\HKjbXH0bYMhcW6lcnXhd4Uhd2ZiQ2LFRlEh[WO2aY\peJk> NGPaWXEzPTV2OEC5PS=>
ThGCs  NYrjO2dtTnWwY4Tpc44hSXO|YYm= M2XDV|Ex6oDMzszN M33ne|TjiIqq NUeySGx2[XWpbXXueJMhUEmIMVGgcIV3\Wy|IIToZZQhf2W{ZTDzeIlufWyjdHXkJIJ6KEOxQ3yy M3XzVVI2PDN|MEK3
ThGCs  MknVSpVv[3Srb36gRZN{[Xl? NVzNRmZNOTEkgJtOwG0> M17JZVTjiIqq MV7pcoNz\WG|ZYOgR49EdDJvaX7keYNm\CCHRF6yxsBo\W6nIHX4dJJme3Orb36= MlnNNlU1OzNyMke=
ThGCs  NVfYV5ZYTnWwY4Tpc44hSXO|YYm= MorHNVDjiIsQvF2= NWr4Xmg5OyCq NYP6fYc5cW6qaXLpeJMhfGinIHXm[oVkfCCxZjDINm8zKG:wIFXEUlIhdVKQQR?= MkPFNlU1OzNyMke=
RBMECs NWq2bo91TnWwY4Tpc44hSXO|YYm= NFjFd4cxNjB3L{CuOU82KM7:TR?= MUiwMlI2KGh? NE\T[ZpqdmO{ZXHz[ZMh[0GPUDDjc45k\W62cnH0bY9v NF\U[2kzPTRzNk[1NS=>
RBMECs NYnrXFd7TnWwY4Tpc44hSXO|YYm= MVy1xsDPxE1? NECxW2EyKGh? MYTicI9kc3NidHjlJIFkfGm4YYTpc44hd2ZiUnjvRU9TV0ONIHnu[JVk\WRiYomgSW1CWC2LSR?= NIHpT|czPTRzNk[1NS=>
RBMECs MU\GeY5kfGmxbjDBd5NigQ>? M2rQRVXDqM7:TR?= NH7y[2gyKGh? MXfwdoV3\W62czD0bIUhTU2DUD3JTU1qdmS3Y3XkJHRGTVJidnHseYUh\GWlcnXhd4U> NFG5OlgzPTRzNk[1NS=>
RBMECs MV;GeY5kfGmxbjDBd5NigQ>? MmDMOeKh|ryP MlXRNUBp MXPwdoV3\W62czD0bIUhcW6lcnXhd4UhcW5iSGLQJIZtfXhiYXPyc5N{KHSqZTDCWGIhcW6mdXPl[EBjgSBiRV3BVE1KUQ>? MkLUNlU1OTZ4NUG=
RBMECs MXvGeY5kfGmxbjDBd5NigQ>? NYjw[3JiPcLizszN NXixc3FHOSCq MXHpcohq[mm2czD0bIUh\GWlcnXhd4VlKG:oIHHtc5VvfCCxZjDaU{0yKGmwIF3Gd{BqdmS3Y3XkJIJ6KEWPQWCtTWk> NX;wTYZCOjV2MU[2OVE>
RBMECs MUjGeY5kfGmxbjDBd5NigQ>? M1j6RVXDqM7:TR?= Mni3NUBp Mn3HdoV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iWl:tNUBlcXO2cnnieZRqd25ic3XlckB4cXSqIFXNRXAuUUlidILlZZRu\W62 MoTFNlU1OTZ4NUG=
RBMECs NFLZ[VFHfW6ldHnvckBCe3OjeR?= NULCS3RTPcLizszN M4H3flEhcA>? MnjCZoxw[2u|IITo[UBGVUGSLVnJMYlv\HWlZXSgZ4hidmenIHnuJG1NSyCyaH;zdIhwenmuYYTpc44> M{nTOFI2PDF4NkWx
RBMECs MkLOSpVv[3Srb36gRZN{[Xl? MXW1xsDPxE1? MYmxJIg> NFL6T4RjdG:la4OgeIhmKGGldHnuJIN6fG:|a3Xs[ZRwdiC{ZXHydoFv\2WvZX70JJNm\W5id3n0bEBGVUGSLVnJJJRz\WG2bXXueOKh MVOyOVQyPjZ3MR?=
Primary bovine chondrocytes M1zaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LhSFXPxE1? NG\KXoU1QCCq MYPy[ZZmenOnczD0bIUhcW6qaXLpeI9zgSCnZn\lZ5Qhd2ZiY3Xs[YNwgGmkIH;uJJBzd2yrZnXyZZRqd25iaX6g[5Jwf3SqIIDsZZRmKGOqb37kdo9kgXSncx?= NXvISZV6OjV2ME[wNVY>
EM1  MVzGeY5kfGmxbjDBd5NigQ>? MUGxOgKBks7:TR?= NHP1WpU1QCCq M4\ONJJm\HWlZYOgeIhmKGW6cILld5Nqd25ib3dCpGxKTsLib4NCpHBVT1N{wrDpcuKhS0GOUj2gc5LDqEWSQVOyMZNqdGWwY3XkJGVOOSClZXzsd:Kh MnTTNlU{Pzh4NkG=
BeWo  M{XNSWZ2dmO2aX;uJGF{e2G7 NITPU5gzOMLiwsXN M3L1UlQ5yqCqwrC= M1nBZ2ROW00EoB?= M{H2V4lv[3KnYYPld{B1cGViYnX0ZU1pS0dicnXs[YF{\Q>? M{PiXlI2OzZ{Mk[w
BeWo  NYTHdHlMTnWwY4Tpc44hSXO|YYm= NGXFc2UzOMLiwsXN Mnr0OFjDqGkEoB?= M1LCS2ROW00EoB?= MV;kc5dvemWpdXzheIV{KHSqZTDs[ZZmdCCxZjDUUWVOTjF4 NV\rfHNSOjV|NkKyOlA>
BeWo  M3P2VmZ2dmO2aX;uJGF{e2G7 NH;aPW4zOMLiwsXN NHm1b2c1QMLiaNMg M{TOemROW00EoB?= M2rkRoRwf26{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJGdEVS1z M3PqVVI2OzZ{Mk[w
granulosa cells MkftSpVv[3Srb36gRZN{[Xl? NIOxcGYyOCEQvF2= NHzORpMyOi9{NDDo NH3RXXJqdmO{ZXHz[ZMhfGinIHzleoVteyCxZtMgVmdUOsLibWLORS=> MYSyOVM{QTFyNR?=
granulosa cells M4nUbGZ2dmO2aX;uJGF{e2G7 Ml76NVAh|ryP NWfrR2pDOTJxMkSgbC=> MXzpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC{ZYDvdpRmeiCjY4Tpeol1gSCob4KgeIhmKGyxbnfld5Qh\nKjZ33lcpQhMOLKkki1OE8sOTiUR2OyMmxWSyl? M3\qWVI2OzN7MUC1
granulosa cells NEDvXpJHfW6ldHnvckBCe3OjeR?= MV:xNEDPxE1? NF70ZW0zPCCq MXzpcoNz\WG|ZYOgeIhmKGmwdHXud4l1gSCxZjDEUmEweHKxdHXpckBkd22ybHX4 MlzQNlU{OzlzMEW=
granulosa cells MXrGeY5kfGmxbjDBd5NigQ>? M2jjUVExKM7:TR?= NWjIZlNqOjRiaB?= NIDkTWtqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDSS3MzKHC{b33veIVzKGGldHn2bZR6 M4L6flI2OzN7MUC1
SK-N-AS  NF71R4NE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF\BUmUyOCEQvF5CpC=> NYf2VpJ2OjRxNEigbC=> NY\NeHd3\W6qYX7j[ZMhfGmvZT3k[ZBmdmSnboTsfUBk\WyudXzhdkB3cWGkaXzpeJnDqA>? MVSyOVI3PjB4Mx?=
SK-N-AS  NEXK[oFHfW6ldHnvckBCe3OjeR?= NX7LfY1iOTBizszNxsA> MmfHNlQhcA>? NWLpU3kycW6lcnXhd4V{KHSqZTDjRW1RKGyndnXsd:Kh NHOxR3YzPTJ4NkC2Ny=>
SK-N-AS  NV3YU3gzTnWwY4Tpc44hSXO|YYm= MojkNVAh|ryPwrC= NX63endyOjRiaB?= NVjUSHdqcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGO7Y3zpckBFOQ>? NWHJPIpyOjV{Nk[wOlM>
SK-N-AS  NGPHbpRHfW6ldHnvckBCe3OjeR?= NX3PdJRvOTBizszNxsA> MlzKN|AhdWmw MnnwbY5lfWOnczDwbI9{eGixconsZZRqd25ib3[g{tIu[2G2ZX7pckApe2W{Nke1LUwheC2JU1uz{tIhMHOnckmpJIFv\CClb37jc41qfGGwdDDobYdp\XJibHX2[Yx{KG:oIHHjeIl3\SxidX7wbI9{eGixconsZZRm\CxizsKtZ4F1\W6rbh?= NXnYN281OjV{Nk[wOlM>
SK-N-AS  NVi5ZXhqTnWwY4Tpc44hSXO|YYm= MXWxNEDPxE4EoB?= NH;S[ngyOC9|MD:2NEBucW5? MVPpcoNz\WG|ZYOgcIV3\Wy|IH;mJJAu|rJvY3H0[Y5qdiBqc3XyOlc2MSCjbnSgbY5lfWOnczDhZ4N2dXWuYYTpc44hd2ZicD5Otk1k[XSnbnnuJEh{\XJ4N{WpJIlvKCiyZYLpLY52[2ynYYKgdoVocW:wcx?= NInYdo8zPTJ4NkC2Ny=>
SK-N-SH MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoXNNVAh|ryPwrC= Mo\wOFghcA>? M3;NNYVvcGGwY3XzJHNMNU5vU1igcoV2em:kbHHzeI9u[SClZXzsJJZq[WKrbHn0fS=> NGToXYQzPTJ4NkC2Ny=>
HEK‐CFTR NF;FVphHfW6ldHnvckBCe3OjeR?= M{PJTVLjiJN3MNMg{txO NXeyfo5xOC1zMjDtbY4> M2C3fWROW00EoB?= Mn3EbY5lfWOnczDhJIRwe2YkgKDk[ZBmdmSnboSgbY9lcWSnIHXm[ox2gMLi MontNlUzPjN{MEe=
L6 M2r5cWZ2dmO2aX;uJGF{e2G7 MnTCOFAhyrWP NFWzfokzPCCq NIjmbVJqdmirYnn0d{BFVUhzLXnu[JVk\WRiQXv0JIFkfGm4YYTpc44> NETZbWMzPTJ2N{W1NC=>
MIN6  M3XvbGZ2dmO2aX;uJGF{e2G7 MWexNEDPxE4EoB?= MYmzJIg> NH34PI5qdmO{ZXHz[ZMhTDNibWLORUBmgHC{ZYPzbY9v MX[yOVI1OTF{NB?=
ventricular cardiomyocytes  NEfnXGpHfW6ldHnvckBCe3OjeR?= MmPqNE4xOS1zMDFOwG0> NFuwbHBqdmO{ZXHz[ZMhKGODTWCgZYNkfW23bHH0bY9v M3XTcVI2OjB|MUGz
ventricular cardiomyocytes  NY\zPG06TnWwY4Tpc44hSXO|YYm= M3i0blAvODFvMUCg{txO MlP4[ZZwc2W|IHHuJIlvd3S{b4DpZ{Bz\XOyb37z[UAyOjEEsUG1KUBi[m:4ZTDiZZNidCC5aYToJIFvKEWFNUFCpI9nKDJwMjFCuW0> NEfuclYzPTJyM{GxNy=>
BeWo  Ml\xSpVv[3Srb36gRZN{[Xl? NF\k[nkzOCEEtV2= M2n0TVQ5KGh? NUi0c2g2TE2VT9Mg NWDDN3RPcW6mdXPld{Bk\WyuIH\1d4lwdg>? M{XobFI2OTh2NEe3
THP-1  MlHiSpVv[3Srb36gRZN{[Xl? NIq3fGYyNzFyIN88US=> NUDqZoZ6OsLiaB?= NVHyWJpXTE2VT9Mg NFf2fpB{fXCycnXzd4V{KE2FUD2xJJBzd2S3Y4Tpc47DqA>? NVHy[XJiOjVzNUS4PFI>
Huh-7 NWPWc2lITnWwY4Tpc44hSXO|YYm= M4rDcVAuOjBizszN NIDUXnAzKGkEoB?= MmPwdoV{fWy2czDpckBiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGNvTYnjJIV5eHKnc4Ppc44h[XRidHjlJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wy| MmfZNlUyODl6M{S=
C6 M4ToSWZ2dmO2aX;uJGF{e2G7 MYmxNEDPxE4EoB?= Mnu1NlAhdWmw M3HHfolv[3KnYYPld{BkSU2SIHHjZ5VufWyjdHnvci=> MWKyOVA3QTRzNx?=
SW480 NYWxNppHTnWwY4Tpc44hSXO|YYm= M3vGd|QxyqEQvF2= MWO0POKhcA>? MWXEUXNQ MWPhZ5RqfmG2ZYOgVHAzSQ>? M33xc|I1QTl5NEWx
HT-29  NEPq[5BHfW6ldHnvckBCe3OjeR?= MY[0NOKh|ryP NHf0XHg1QMLiaB?= M3z4ZmROW09? MWfhZ5RqfmG2ZYOgVHAzSQ>? NEXTVJozPDl7N{S1NS=>
SW480 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjtXGlEPDEEoN88US=> MUewMVczKGh? Mlv6SG1UVw>? MW\pcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NVnPb5ZkOjR7OUe0OVE>
HT-29  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXXNGg1OMLizszN M4fSWlAuPzJiaB?= NETUdZJFVVOR NIPMRZdqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 NGLFfFAzPDl7N{S1NS=>
SW480 MYPGeY5kfGmxbjDBd5NigQ>? NU\3TZJpPDEEoN88US=> Mn[xO{Bl MXXEUXNQ MUny[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi NXS4SXdwOjR7OUe0OVE>
HT-29  NH;MNHZHfW6ldHnvckBCe3OjeR?= MljMOFDDqM7:TR?= MoLmO{Bl M3;lPGROW09? NIrtS4Rz\WS3Y3XzJINwdG:wb4PwbIVz\SCob4LtZZRqd25iY3HwZYJqdGm2edMg M2\Oe|I1QTl5NEWx
SW480 M1PC[2Fxd3C2b4Ppd{BCe3OjeR?= M121TFQxyqEQvF2= MUS0POKhcA>? MVrEUXNQ NVT4fGZwcW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 NWraSnE5OjR7OUe0OVE>
HT-29  NIjL[ldCeG:ydH;zbZMhSXO|YYm= MmTXOFDDqM7:TR?= NFrlOm41QMLiaB?= MX;EUXNQ NX\QdmhbcW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 M3vWO|I1QTl5NEWx
SW480 NXPGbWtkSXCxcITvd4l{KEG|c3H5 Mnv0OFDDqM7:TR?= NWrIVpA{PDkEoHi= MVHEUXNQ NYntXoRycW6mdXPld{BkcGGwZ3XzJIlvKHSqZTDwbI9{eGixconsZZRqd25ic4TheJV{KG:oIGDQNmEhfGG{Z3X0dy=> NHvLUpYzPDl7N{S1NS=>
HT-29  NG[4XnJCeG:ydH;zbZMhSXO|YYm= NHO5eGE1OMLizszN M2DQO|Q5yqCq M3XhdGROW09? NXfSUlY{cW6mdXPld{BkcGGwZ3XzJIlvKHSqZTDwbI9{eGixconsZZRqd25ic4TheJV{KG:oIGDQNmEhfGG{Z3X0dy=> M4PiSFI1QTl5NEWx

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
保管
in solvent
別名 Coleonol

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null Not Applicable
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null Not Applicable

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Forskolinを買う | Forskolin ic50 | Forskolin供給者 | Forskolinを購入する | Forskolin費用 | Forskolin生産者 | オーダーForskolin | Forskolin化学構造 | Forskolin分子量 | Forskolin代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID